Key features and details
- Mouse monoclonal [B2] to CRALBP (HRP)
- Suitable for: WB
- Reacts with: Rat
- Conjugation: HRP
- Isotype: IgG2a
Product nameAnti-CRALBP antibody [B2] (HRP)
See all CRALBP primary antibodies
DescriptionMouse monoclonal [B2] to CRALBP (HRP)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Rat
Predicted to work with: Mouse, Cow, Human, Pig, Monkey
Recombinant full length protein corresponding to Human CRALBP.
- WB: Rat eye lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: PBS, 1% BSA, 30% Glycerol
Concentration information loading...
Our Abpromise guarantee covers the use of ab199992 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/5000. Detects a band of approximately 36 kDa (predicted molecular weight: 36 kDa).|
FunctionSoluble retinoid carrier essential the proper function of both rod and cone photoreceptors. Participates in the regeneration of active 11-cis-retinol and 11-cis-retinaldehyde, from the inactive 11-trans products of the rhodopsin photocycle and in the de novo synthesis of these retinoids from 11-trans metabolic precursors. The cycling of retinoids between photoreceptor and adjacent pigment epithelium cells is known as the 'visual cycle'.
Tissue specificityRetina and pineal gland. Not present in photoreceptor cells but is expressed abundantly in the adjacent retinal pigment epithelium (RPE) and in the Mueller glial cells of the retina.
Involvement in diseaseDefects in RLBP1 are a cause of retinitis pigmentosa autosomal recessive (ARRP) [MIM:268000]. RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well.
Defects in RLBP1 are the cause of Bothnia retinal dystrophy (BRD) [MIM:607475]; also known as Vasterbotten dystrophy. Affected individuals show night blindness from early childhood with features consistent with retinitis punctata albescens and macular degeneration.
Defects in RLBP1 are the cause of rod-cone dystrophy Newfoundland (NFRCD) [MIM:607476]. NFRCD is a retinal dystrophy reminiscent of retinitis punctata albescens but with a substantially lower age at onset and more-rapid and distinctive progression. Rod-cone dystrophies results from initial loss of rod photoreceptors, later followed by cone photoreceptors loss.
Defects in RLBP1 are a cause of fundus albipunctatus (FA) [MIM:136880]. FA is a rare form of stationary night blindness characterized by a delay in the regeneration of cone and rod photopigments.
Sequence similaritiesContains 1 CRAL-TRIO domain.
- Information by UniProt
- Cellular retinaldehyde binding protein 1 antibody
- Cellular retinaldehyde binding protein antibody
- Cellular retinaldehyde-binding protein antibody
Anti-CRALBP antibody [B2] (HRP) (ab199992) at 1/5000 dilution + Eye (Rat) Tissue Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 36 kDa
Observed band size: 36 kDa
Exposure time: 3 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab199992 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab199992 has not yet been referenced specifically in any publications.